Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment

Update Il y a 4 ans
Reference: NCT01585584

Woman and Man

  • | Country :
  • Canada
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to test the potential antiviral efficacy of triple-combination therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype 3 who previously failed Peginterferon α + ribavirin (non-responders or relapsers).


Inclusion criteria

  • Hepatitis C

Links